Radiation-induced hypothyroidism in patients with breast cancer: a retrospective analysis of 243 cases

Basit Öğe Kaydı
dc.contributor.authorKanyilmaz, Gul
dc.contributor.authorAktan, Meryem
dc.contributor.authorKoc, Mehmet
dc.contributor.authorDemir, Hikmettin
dc.contributor.authorDemir, Lutfi Saltuk
dc.date.accessioned2024-02-23T14:13:11Z
dc.date.available2024-02-23T14:13:11Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractThis study aims to estimate the incidence of hypothyroidism (HT) and to evaluate the predictors affecting the development of HT after radiotherapy (RT) for breast cancer, with a focus on radiation dose-volumetric parameters. Between 2009 and 2015, 243 patients undergoing RT for breast cancer were retrospectively analyzed. Free triiodothyronine (FT3), free thyroxin (FT4), and thyrotropin (TSH) were monitored before and after RT. The relation between the doses to thyroid gland (D-mean, D-max, D-min), percentage of thyroid volume receiving > 10 Gy, 20 Gy, 30 Gy, 40 Gy, and 50 Gy (V10 to V50), absolute thyroid volume, and HT were analyzed. The risk of HT according to radiation fields and the other clinic factors were also evaluated. The median follow-up was 41 (range; 6 to 130) months. Sixty-seven percent of the patients received RT to the breast/chest wall and ipsilateral supraclavicular fossa. Of 243 patients, 51 (21%) were diagnosed with HT. The median time to the onset of HT was 27 (range; 5 to 64) months. There were no significant relationships observed between Dmin or V10 to V50 and HT. The surgery type, clinical stage, nodal status, RT field, Dmean, and Dmax were statistically significant predictors for HT in univariate analysis. The Dmean was the only prognostic factor predicting HT in multivariate analysis, and Dmean > 21 Gy was a threshold value for the evolvement of HT. In this study, we present evidence that postoperative irradiation of patients with breast cancer may frequently lead to HT. Patients who have received RT for breast cancer, especially irradiation on the supraclavicular region, may require thyroid function screening after RT. (C) 2017 American Association of Medical Dosimetrists.en_US
dc.identifier.doi10.1016/j.meddos.2017.03.003
dc.identifier.endpage196en_US
dc.identifier.issn0958-3947
dc.identifier.issn1873-4022
dc.identifier.issue3en_US
dc.identifier.pmid28502654en_US
dc.identifier.scopus2-s2.0-85019156369en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage190en_US
dc.identifier.urihttps://doi.org/10.1016/j.meddos.2017.03.003
dc.identifier.urihttps://hdl.handle.net/20.500.12452/12342
dc.identifier.volume42en_US
dc.identifier.wosWOS:000411424200005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofMedical Dosimetryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast Canceren_US
dc.subjectDose-Volumetric Analysisen_US
dc.subjectHypothyroidismen_US
dc.subjectRadiotherapyen_US
dc.titleRadiation-induced hypothyroidism in patients with breast cancer: a retrospective analysis of 243 casesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu